N
Nikolaos Perakakis
Researcher at Beth Israel Deaconess Medical Center
Publications - 74
Citations - 2364
Nikolaos Perakakis is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 48 publications receiving 1412 citations. Previous affiliations of Nikolaos Perakakis include Harvard University & VA Boston Healthcare System.
Papers
More filters
Journal ArticleDOI
Physiology and role of irisin in glucose homeostasis
Nikolaos Perakakis,Georgios Triantafyllou,José Manuel Fernández-Real,Joo Young Huh,Kyung Hee Park,Jochen Seufert,Christos S. Mantzoros,Christos S. Mantzoros +7 more
TL;DR: This Review presents the current knowledge on the physiology of irisin and its role in glucose homeostasis, and describes the mechanisms involved in the synthesis, secretion, circulation and regulation of irisin, and the controversies regarding the measurement.
Journal ArticleDOI
Obesity as a Disease.
Jagriti Upadhyay,Jagriti Upadhyay,Olivia M. Farr,Nikolaos Perakakis,Wael Ghaly,Christos S. Mantzoros +5 more
TL;DR: The mechanisms of obesity and its related comorbidities are reviewed, with a focus on overweight men and women.
Journal ArticleDOI
Irisin in metabolic diseases
Stergios A. Polyzos,Athanasios D. Anastasilakis,Zoe Efstathiadou,Polyzois Makras,Nikolaos Perakakis,Jannis Kountouras,Christos S. Mantzoros +6 more
TL;DR: Irisin remains an appealing molecule from a pathophysiological point of view and an appealing therapeutic target for metabolic diseases, albeit much research is still needed.
Journal ArticleDOI
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi,Olivia M. Farr,Stergios A. Polyzos,Nikolaos Perakakis,Eric Nolen-Doerr,Aimilia Eirini Papathanasiou,Christos S. Mantzoros +6 more
TL;DR: Evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized and anti-obesity agents in the pipeline for potential future therapeutic use are presented.
Journal ArticleDOI
Pharmacotherapy of type 2 diabetes: An update.
Jagriti Upadhyay,Stergios A. Polyzos,Nikolaos Perakakis,Bindiya Thakkar,Stavroula A Paschou,Niki Katsiki,Patricia Underwood,Kyung Hee Park,Jochen Seufert,Eun Seok Kang,Elliot Sternthal,Asterios Karagiannis,Christos S. Mantzoros +12 more
TL;DR: The aim of this narrative review is to summarize the pharmacologic treatment options available for patients with T2DM, outlining medication effects, side effects, glycemic control, effect on weight, indications and contraindications, and use in selected populations.